About the Company
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZIOP News
Alaunos Therapeutics Inc TCRT
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split
Alaunos Therapeutics (TCRT) has released an update. Alaunos Therapeutics, Inc. has approved a reverse stock split of its common stock at a ratio of 1-for-15, to take effect on January 31 ...
Alaunos Therapeutics, Inc. (TCRT) stock forecast and price target
Find the latest Alaunos Therapeutics, Inc. TCRT analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Alaunos Therapeutics, Inc. (WEK.MU)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Why AMC Entertainment Holdings Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket
Kazia Therapeutics Ltd (NASDAQ: KZIA) fell 6.8% to $0.96 in pre-market trading. Alaunos Therapeutics Inc (NASDAQ: TCRT) shares fell 5.7% to $0.59 in pre-market trading. Now Read This: Top 4 ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Alaunos Therapeutics Inc TCRT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TCRT Alaunos Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Alaunos Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Alaunos Therapeutics, Inc. Common Stock (TCRT)
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
Loading the latest forecasts...